AstraZeneca rejects Pfizer's "final" bid

Share this article:

Managers from AstraZeneca rebuffed another offer to relinquish their autonomy, saying Pfizer's latest bid for the British drugmaker, a Friday night proposal valued at 69.4 billion pounds ($117 billion), was too low. The rejection of the bid, which Pfizer said was final, left the two drugmakers in a stalemate over a deal that would have created the world's largest drugmaker.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters